Malignant Metastatic Eccrine Poroma: Proposal for a New Therapeutic Protocol
Malignant Metastatic Eccrine Poroma: Proposal for a New Therapeutic Protocol
复制标题
恶性转移性小汗腺孔瘤：新治疗方案的提案
作者：
A. Barzi;S. Ruggeri;F. Recchia;I. Bertoldi
背景：恶性转移性小汗腺汗孔瘤是一种非常罕见的皮肤肿瘤，因此文献中关于这种肿瘤（也称为汗孔癌）治疗的参考文献非常少。目的探讨转移性汗孔癌的新治疗方案，并强调维生素A类似物的疗效。方法根据1例恶性小汗腺汗孔瘤伴区域淋巴结转移的临床病例进行分析。结果采用我们的新化疗方案，3个月后转移进展被阻止，并维持缓解至治疗的第10个月。结论异维A酸联合干扰素治疗转移性小汗腺汗孔瘤的新方案证实了综合化疗的优越性。尽管使用了高剂量的合成类维生素A，但在相当长的时间内，尽管不完全缓解，药物耐受性良好，以及最新一代合成类维生素A无疑具有主要的抗肿瘤作用，我们认为这些发现可能是进一步实验验证这种侵袭性皮肤肿瘤治疗的良好起点。
BACKGROUND Malignant metastatic eccrine poroma is a very rare cutaneous neoplasm, and consequently the references in the literature regarding the treatment of this tumor, known also as porocarcinoma, are very poor. OBJECTIVE To call attention to a new therapeutic protocol in the treatment of metastatic porocarcinoma, as well as to underline an antineoplastic efficacy of vitamin A analogues. METHODS The results are presented on the basis of the clinical case of a malignant eccrine poroma with metastatic regional lymph nodes. RESULTS With our new chemotherapeutic protocol, arrest of the metastatic progression was achieved after 3 months and the remission was maintained until the 10th month of therapy. CONCLUSIONS A new chemotherapy protocol consisting of isotretinoin and interferon alpha has confirmed the advantages of polychemotherapy in the treatment of metastatic malignant eccrine poroma. On the basis of the considerably long, although incomplete, remission with good drug tolerance in spite of the high doses used as well as the undoubtedly major antineoplastic strength of the latest generation of synthetic retinoids, we feel that these findings could be a good starting point for further experimental verifications of the therapy of this aggressive cutaneous neoplasm.
影响因子：
158.5
作者：
HONG, WK;LIPPMAN, SM;GOEPFERT, H
通讯作者：
GOEPFERT, H